New hope for tough lung cancer? early trial launches in china
NCT ID NCT06799286
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This early-stage study tests a new drug combination (BMS-986489) in 10 Chinese adults with small cell lung cancer that has returned or stopped responding to treatment. The main goals are to check safety and how the drug moves through the body, while also looking for signs that it might shrink tumors. This is a first step to see if the treatment is promising enough for larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0001
Linyi, Shandong, 276001, China
-
Local Institution - 0002
Shanghai, 200120, China
-
Local Institution - 0003
Jinan, Shandong, 250117, China
-
Local Institution - 0004
Beijing, Beijing Municipality, 100142, China
-
Local Institution - 0005
Hangzhou, Zhejiang, 310016, China
Conditions
Explore the condition pages connected to this study.